DDX3X and neoplasm: While the precise molecular cascade (e.g., whether HMGB1 promotes DDX3 degradation via ubiquitination) requires further investigation, our current data support a model in which HMGB1-driven DDX3 suppression releases MAPK pathway inhibition, thereby driving tumor progression.